Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
Launched by WEST CHINA HOSPITAL · Jul 28, 2010
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Creatinine clearance 30 to 90 mL/min/1.73 m2, with variations of less than 20 percent in the 2 weeks before the screening evaluation.
- • Diagnosed hypertension according to guidelines or having taken anti-hypertension drugs.
- • Aged between 65 and 85 years.
- • Willingness to provide written, informed consent.
- • Ability to adhere to study protocol.
- Exclusion Criteria:
- • Secondary hypertension.
- • Diabetes mellitus.
- • Atrial flutter/atrial fibrillation.
- • Symptoms of congestive heart failure (NYHA III-IV) or there is evidence that left ventricular EF \< 40%.
- • Recent (\< 6 months) myocardial infarction or cerebrovascular ischemic symptoms.
- • Recent (\< 3 months) or planned coronary revascularization: PCI (percutaneous coronary intervention)/CABG (coronary artery by-pass graft).
- • Severe valvular heart disease.
- • History of hypersensitivity to indapamide, thiazides or to any of the components of the products.
- • Any current condition or other disease known to interfere significantly with the absorption, distribution, metabolism or excretion of study drugs.
- • Participation to another investigational study in the last 3 months.
About West China Hospital
West China Hospital, affiliated with Sichuan University, is a leading medical institution renowned for its comprehensive healthcare services, advanced research initiatives, and commitment to medical education. As a prominent clinical trial sponsor, the hospital leverages its extensive resources and expertise to facilitate innovative research in various therapeutic areas. With a focus on improving patient outcomes and advancing medical knowledge, West China Hospital collaborates with various stakeholders to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Its state-of-the-art facilities and multidisciplinary teams ensure the successful execution of trials, contributing significantly to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Trial Officials
Xiao P Chen, master
Principal Investigator
West China Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials